Table 2 Characteristics of industry-sponsored clinical trials performed exclusively within one major geographic group ^a

Median study sites, N (IQR)

1 ^c

1 ^c

1 ^c

2 ^c

1

(1–2)

(1–3)

(1–4)

(1–9)

(1–9)

Median subjects enrolled, N (IQR)

100 ^c

183 ^c

142 ^c

120 ^c

71

(48–200)

(90–400)

(50–300)

(47–259)

(33–188)

Double-blinded, N (%)

191 ^c

73 ^c

502 ^c

168

9938

(46.9)

(44.7)

(44.1)

(65.6)

(61.1)

Industry as lead funder, N (%)

345 ^c

115 ^c

998 ^c

236 ^c

13 133

(84.8)

(70.5)

(87.7)

(92.2)

(80.8)

Phase 3 or 4, N (%)

250 ^c

73 ^c

589 ^c

104 ^c

5345

(61.6)

(44.7)

(51.7)

(40.6)

(32.9)

Paediatric ^b N (%)

42 ^c

51 ^c

120 ^c

28 ^c

699

(10.3)

(31.3)

(10.5)

(10.9)

(4.2)